Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
Open Access
- 20 January 2020
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-19
Abstract
Emergence of an aggressive androgen receptor (AR)-independent neuroendocrine prostate cancer (NEPC) after androgen-deprivation therapy (ADT) is well-known. Nevertheless, the majority of advanced-stage prostate cancer patients, including those with SPINK1-positive subtype, are treated with AR-antagonists. Here, we show AR and its corepressor, REST, function as transcriptional-repressors of SPINK1, and AR-antagonists alleviate this repression leading to SPINK1 upregulation. Increased SOX2 expression during NE-transdifferentiation transactivates SPINK1, a critical-player for maintenance of NE-phenotype. SPINK1 elicits epithelial-mesenchymal-transition, stemness and cellular-plasticity. Conversely, pharmacological Casein Kinase-1 inhibition stabilizes REST, which in cooperation with AR causes SPINK1 transcriptional-repression and impedes SPINK1-mediated oncogenesis. Elevated levels of SPINK1 and NEPC markers are observed in the tumors of AR-antagonists treated mice, and in a subset of NEPC patients, implicating a plausible role of SPINK1 in treatment-related NEPC. Collectively, our findings provide an explanation for the paradoxical clinical-outcomes after ADT, possibly due to SPINK1 upregulation, and offers a strategy for adjuvant therapies.Keywords
All Related Versions
Funding Information
- DBT India Alliance (IA/I(S)/12/2/500635)
This publication has 71 references indexed in Scilit:
- From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancerThe Journal of Pathology, 2012
- Repressor element-1 silencing transcription factor (REST)-dependent epigenetic remodeling is critical to ischemia-induced neuronal deathProceedings of the National Academy of Sciences, 2012
- Cooperation between Polycomb and androgen receptor during oncogenic transformationGenome Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Therapeutic Targeting of SPINK1-Positive Prostate CancerScience Translational Medicine, 2011
- Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaNature Medicine, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell, 2008
- SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradationNature, 2008
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005